|
Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, has announced that it will host a research & development (R&D) update in Shanghai, China, and through webcast on October 31, 2025.
During the event, Dr. Michael Shi, executive vice president and head of R&D and chief medical officer of Hutchmed, will share insights into the company’s research & development strategy and vision. This will include an overview of the company’s antibody targeted therapy conjugates platform, featuring its lead candidate HMPL-A251, as well as updates on late-stage pipeline development.
The in-person event will be held in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and conducted in Chinese (Putonghua). A live webcast will be available concurrently. Attendance at the in-person event is by invitation only.
A webcast in English will be held from 8:00 p.m. HKT/ 8:00 a.m. EDT/12:00 noon GMT on Friday, October 31, for approximately one hour.
Both webcasts will be available live via the company website at www.hutch-med.com/event/. A replay will also be available on the website shortly after the event.
|